OR WAIT null SECS
April 02, 2023
A further setback to the publication of the pharmaceutical legislative changes in Europe may mean time is running out for appropriate review before 2024 parliamentary elections.
Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely.
March 31, 2023
FDA has approved Evkeeza for young children with homozygous familial hypercholesterolemia.
March 30, 2023
Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.
CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.
Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.
Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel.
The Supreme Court heard oral arguments concerning the legitimacy of “genus clauses” in bio/pharma patents.
March 29, 2023
Narcan, from Emergent Solutions, will be the first naloxone product permitted for use without prescription by FDA.
March 27, 2023
PharmaBlock has opened a new R&D facility in Pennsylvania, expanding its capacity to deliver GMP projects.